Holen Sie sich die Stockscreener-App
13.80
0.04%
0.005
Schlusskurs vom Vortag:
$13.79
Offen:
$13.8
24-Stunden-Volumen:
271.78K
Relative Volume:
0.87
Marktkapitalisierung:
$694.99M
Einnahmen:
$62.02M
Nettoeinkommen (Verlust:
$-45.65M
KGV:
-15.00
EPS:
-0.92
Netto-Cashflow:
$-9.60M
1W Leistung:
+2.60%
1M Leistung:
+25.11%
6M Leistung:
+51.98%
1J Leistung:
+69.53%
1-Tages-Spanne:
$13.71
$13.96
1-Wochen-Bereich:
$13.26
$14.27
52-Wochen-Spanne:
$7.88
$14.30
Theravance Biopharma Inc Stock (TBPH) Company Profile
Firmenname
Theravance Biopharma Inc
Sektor
Branche
Telefon
650-808-6000
Adresse
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Vergleichen Sie TBPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
13.80 | 685.42M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.18 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.65 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.20 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
708.09 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.91 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Eingeleitet | BTIG Research | Buy |
| 2024-01-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Eingeleitet | Cowen | Outperform |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-06 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-29 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-12-21 | Eingeleitet | Needham | Buy |
| 2016-11-03 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-10-12 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Eingeleitet | Guggenheim | Buy |
| 2016-06-20 | Bestätigt | Leerink Partners | Outperform |
| 2016-05-12 | Eingeleitet | Leerink Partners | Outperform |
| 2016-05-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
Alle ansehen
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
Risk vs reward if holding onto Theravance Biopharma Inc.Earnings Miss & Real-Time Volume Analysis Alerts - Newser
Is Theravance Biopharma Inc. trending in predictive chart models2025 AllTime Highs & Free Daily Entry Point Trade Alerts - Newser
Is Theravance Biopharma Inc. stock a good hedge against inflationPortfolio Performance Summary & Fast Entry High Yield Tips - Newser
Visualizing Theravance Biopharma Inc. stock with heatmapsMarket Rally & Free Community Supported Trade Ideas - Newser
Using data tools to time your Theravance Biopharma Inc. exitEarnings Performance Report & Capital Efficiency Focused Ideas - Newser
Automated trading signals detected on Theravance Biopharma Inc.Trade Exit Report & Fast Exit Strategy with Risk Control - Newser
Theravance Biopharma stock rating reiterated at Buy by BTIG - Investing.com Nigeria
Theravance Completes Enrollment in Phase 3 CYPRESS Study - MSN
Viatris Inc. shares fall 1.13% intraday as Theravance Biopharma completes enrollment in pivotal Phase 3 trial. - AInvest
Published on: 2025-08-25 06:51:25 - Newser
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy - PR Newswire
Earnings visualization tools for Theravance Biopharma Inc.Trade Exit Summary & High Return Trade Opportunity Guides - Newser
Is Theravance Biopharma Inc. still worth holding after the dipCEO Change & Consistent Profit Trade Alerts - Newser
What moving averages say about Theravance Biopharma Inc.July 2025 Sentiment & Smart Money Movement Alerts - Newser
Using data models to predict Theravance Biopharma Inc. stock movement2025 Key Lessons & Free Accurate Trade Setup Notifications - Newser
What are the future prospects of Theravance Biopharma Inc.Chart Signals & Growth Focused Stock Pick Reports - theviewers.co.kr
Will Breakout in Theravance Biopharma Inc. Sustain Through Next WeekWeekly Trade Report & AI Optimized Trade Strategies - beatles.ru
Bull Run: Can Theravance Biopharma Inc. be recession proofJuly 2025 Price Swings & Stepwise Swing Trade Plans - theviewers.co.kr
Theravance Biopharma Inc. Stock Recovery Path — Analyst Breakdown2025 Market Sentiment & AI Driven Price Forecasts - 더경남뉴스
Theravance Biopharma Maintains Buy Rating and $26 Price Target - AInvest
Theravance Biopharma shares fall 1.05% after-hours following settlement with Cipla. - AInvest
Theravance Biopharma Settles Patent Dispute with Cipla - TipRanks
Theravance Biopharma reaches patent settlement with Cipla on YUPELRI inhalation - Investing.com
Using RSI to spot recovery in Theravance Biopharma Inc.New Guidance & Safe Entry Point Alerts - Newser
What’s the recovery path for long term holders of Theravance Biopharma Inc.July 2025 Summary & Real-Time Volume Analysis Alerts - Newser
Does Theravance Biopharma Inc. qualify in momentum factor screeningJuly 2025 Rallies & Verified Entry Point Detection - Newser
Theravance Biopharma Inc.’s volatility index tracking explainedWeekly Market Outlook & High Accuracy Buy Signal Tips - Newser
Best data tools to analyze Theravance Biopharma Inc. stock2025 Volatility Report & Proven Capital Preservation Tips - Newser
Is Theravance Biopharma Inc. a momentum stock2025 Winners & Losers & Daily Technical Stock Forecast Reports - classian.co.kr
What earnings revisions data tells us about Theravance Biopharma Inc.2025 Volatility Report & AI Powered Buy/Sell Recommendations - Newser
Using Ichimoku Cloud for Theravance Biopharma Inc. technicals2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
Is Theravance Biopharma Inc. stock undervalued right now2025 Market WrapUp & Low Risk Entry Point Tips - 클래시안
Tools to monitor Theravance Biopharma Inc. recovery probabilityJuly 2025 Action & Daily Profit Focused Stock Screening - Newser
How Theravance Biopharma Inc. stock performs during market volatilityJuly 2025 Setups & High Accuracy Investment Signals - Newser
Candlestick Signal Suggests Reversal in Theravance Biopharma Inc.2025 Volume Leaders & Real-Time Volume Analysis Alerts - metal.it
Leerink Partners Reaffirms Their Hold Rating on Theravance Biopharma (TBPH) - The Globe and Mail
Theravance Biopharma (NASDAQ:TBPH) Rating Increased to Strong-Buy at Wall Street Zen - Defense World
What institutional flow reveals about Theravance Biopharma Inc.Weekly Investment Summary & Consistent Income Trade Ideas - Newser
Real time social sentiment graph for Theravance Biopharma Inc.2025 Top Decliners & AI Driven Price Predictions - Newser
Candlestick Reversal Detected on Theravance Biopharma Inc.’s ChartJuly 2025 Fed Impact & Reliable Volume Spike Alerts - metal.it
What makes Theravance Biopharma Inc. stock price move sharplyJuly 2025 Snapshot & Short-Term Trading Opportunity Alerts - thegnnews.com
H.C. Wainwright Maintains Buy Rating for Theravance Biopharma with $15 Price Target - AInvest
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
H.C. Wainwright Sticks to Their Buy Rating for Theravance Biopharma (TBPH) - The Globe and Mail
The 11% Return This Week Takes Theravance Biopharma's (NASDAQ:TBPH) Shareholders One-year Gains to 51% - 富途牛牛
Theravance Biopharma Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Theravance Biopharma (NASDAQ:TBPH) shareholder returns have been respectable, earning 51% in 1 year - simplywall.st
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Purchased by XTX Topco Ltd - Defense World
Theravance Biopharma’s Earnings Call Highlights Strategic Gains - TipRanks
Theravance Biopharma, Inc. SEC 10-Q Report - TradingView
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
Finanzdaten der Theravance Biopharma Inc-Aktie (TBPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.95%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):